Avinash Kumar Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Avinash Kumar Singh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Manju Sharma
Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
5 shared publications Arya Vidyadhari
4 shared publicationsDinesh Bhurani
Rajiv Gandhi Cancer Institute and Research Centre
3 shared publicationsNarendra Agrawal
Rajiv Gandhi Cancer Institute and Research Centre
3 shared publicationsRayaz Ahmed
Rajiv Gandhi Cancer Institute and Research Centre
3 shared publicationsAnoop Kumar
Delhi Pharmaceutical Sciences and Research University (DPSRU)
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by IntechOpen
Nanofiber-Driven Approaches in Tissue Engineering and Regenerative Medicine
Nanofiber, a novel approach in tissue engineering and regenerative medicine, emphasizes versatility in structure, drug entrapment capabilities, and advanced fabrication techniques that architect a biomimetic scaffold which supports tissue repair and regeneration. Due to the extensive surface area, controlled porosity, adherence to the cells and correspondence with the biological scaffold, nanofiber involves itself in optimal cell proliferation and differentiation. This nanofiber-driven approach prospects other designing methods (such as electrospinning), surface modification, and the incorporation of active ingredients to improve therapeutic responses. The promising objective for the management of healing wounds, bone and cartilage regeneration, normal tissue engineering, and advanced drug delivery emerges as the translational approach of nanofiber mats in novel regenerative medicine.
- 4 September 2026
- Published by IntechOpen
Open AccessNanofiber-Driven Approaches in Tissue Engineering and Regenerative Medicine
Nanofiber, a novel approach in tissue engineering and regenerative medicine, emphasizes versatility in structure, drug entrapment capabilities, and advanced fabrication techniques that architect a biomimetic scaffold which supports tissue repair and regeneration. Due to the extensive surface area, controlled porosity, adherence to the cells and correspondence with the biological scaffold, nanofiber involves itself in optimal cell proliferation and differentiation. This nanofiber-driven approach prospects other designing methods (such as electrospinning), surface modification, and the incorporation of active ingredients to improve therapeutic responses. The promising objective for the management of healing wounds, bone and cartilage regeneration, normal tissue engineering, and advanced drug delivery emerges as the translational approach of nanofiber mats in novel regenerative medicine.
- Open Access
- 31 January 2024
- Published by Wiley
Prevalence of anemia among chronic myeloid leukemia patients treated with Imatinib: A evidence based meta-analysis.
Aim- Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear. The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib. Methods- The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st January 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% C. I was calculated using StatsDirect Statistical analysis software V.3. Results A total of 18 studies containing 3,537 patients (male-1912 and female-1478) were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion: The physician should also take care of anemia while treating CML patients with imatinib. Anemia is a major concern associated with CML patients treated with Imatinib.
- 31 January 2024
- Published by Wiley
Open AccessPrevalence of anemia among chronic myeloid leukemia patients treated with Imatinib: A evidence based meta-analysis.
Aim- Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear. The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib. Methods- The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st January 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% C. I was calculated using StatsDirect Statistical analysis software V.3. Results A total of 18 studies containing 3,537 patients (male-1912 and female-1478) were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high. Conclusion: The physician should also take care of anemia while treating CML patients with imatinib. Anemia is a major concern associated with CML patients treated with Imatinib.
- Open Access
- 23 September 2023
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 24
Drug-loaded electrospun nanofiber for Vulvovaginal candidiasis: A systematic literature review
- 23 September 2023
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 24
Open AccessDrug-loaded electrospun nanofiber for Vulvovaginal candidiasis: A systematic literature review
- 2 March 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (8) , 1928-1934
Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients
Purpose: In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia. Methods: The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22. Results: In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05). Conclusion: We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.
- 2 March 2023
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 29 (8) , 1928-1934
Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients
Purpose: In this study, we investigate renal function and anaemia during imatinib treatment in patients with chronic myeloid leukaemia. Methods: The patients with chronic myeloid leukaemia with chronic phase who had been treated with only imatinib for 12 months at Rajiv Gandhi Cancer Institute and Research Centre (New Delhi, India) were enrolled and prospectively analysed. The chronic renal impairment parameters, including estimated glomerular filtration rate and haemoglobin levels for anaemia from June 2020 to June 2022, were monitored in newly diagnosed in patients with chronic myeloid leukaemia-chronic phase. The data were analysed by SPSS software version 22. Results: In total 55 patients with chronic myeloid leukaemia chronic phase who had been on imatinib for 12 months were monitored. The mean estimated glomerular filtration rate was significantly decreased (74 ± 14 to 59 ± 12 mL/min/1.73m2, p < 0.001) with a decrease in mean haemoglobin levels after 12 months (10.9 ± 2.01 to 9.0 ± 1.02, p < 0.004). The decreased estimated glomerular filtration rate was negatively correlated with haemoglobin levels after 1 year of imatinib administration (correlation coefficient = 0.892, R2 = 0.7976, p < 0.05). Conclusion: We recommended close monitoring of renal function and haemoglobin levels in patients with chronic myeloid leukaemia patients.
- 21 July 2022
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 4 (1) , 1-6
Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience
- 21 July 2022
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 4 (1) , 1-6
Imatinib and Patient-Related Outcomes in Chronic Myeloid Leukemia: A Single Centric Experience
- Open Access
- 30 June 2022
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 16, 101097
Role of colchicine in the management of COVID-19 patients: A meta-analysis of cohort and randomized controlled trials
- 30 June 2022
- Published by Elsevier in Clinical Epidemiology and Global Health
- Vol. 16, 101097
Open AccessRole of colchicine in the management of COVID-19 patients: A meta-analysis of cohort and randomized controlled trials
- Open Access
- 14 March 2022
- Published by Springer Nature in Research Square
Assessment of Patients Health-Related Quality of Life During Complications of Pregnancy in a Tertiary Care Teaching Hospital: a Prospective Study
Background and Objective: Pregnancy has undesirable effects on women lives which lead to reduction in quality of life. Assessment of Quality of Life is necessary among pregnant women because of association with the various complications. Hence, the present study was conducted to evaluate the patient’s health-related quality of life during complications of pregnancy. Method: A prospective observational single centered study was conducted on 81 pregnant women who were diagnosed with complications (Anemia, UTI, Pre-eclampsia and Hyperemesis gravid arum) in Obstetrics & Gynecology department of NIMS Hospital, Jaipur, (Rajasthan). Result: The mean score of physical component scale (PCS) and mental component scale (MCS) was found to be 58.43±0.70 and 75.8±1.25 respectively. The mean score at the time of discharge were physical functioning 69.8±13.77, role limitation due to physical problems 79.01±16.15, role limitation due to emotional problems 68.00±17.10, vitality 48.68±7.30, mental health 98.64±4.25, social functioning 87.22±18.71, bodily pain 80.61±12.67, general health 72.5±4.06 and reported health transition 82.71±12.89 and overall score at p-value was found to be significant. Conclusion: HRQoL of pregnant women associated with complications has been improved where mental health tends to recover more quickly than physical health. Keywords: Quality of Life; Anemia; UTI; Pre-eclampsia; Hyperemesis gravidarum.
- 14 March 2022
- Published by Springer Nature in Research Square
Open AccessAssessment of Patients Health-Related Quality of Life During Complications of Pregnancy in a Tertiary Care Teaching Hospital: a Prospective Study
Background and Objective: Pregnancy has undesirable effects on women lives which lead to reduction in quality of life. Assessment of Quality of Life is necessary among pregnant women because of association with the various complications. Hence, the present study was conducted to evaluate the patient’s health-related quality of life during complications of pregnancy. Method: A prospective observational single centered study was conducted on 81 pregnant women who were diagnosed with complications (Anemia, UTI, Pre-eclampsia and Hyperemesis gravid arum) in Obstetrics & Gynecology department of NIMS Hospital, Jaipur, (Rajasthan). Result: The mean score of physical component scale (PCS) and mental component scale (MCS) was found to be 58.43±0.70 and 75.8±1.25 respectively. The mean score at the time of discharge were physical functioning 69.8±13.77, role limitation due to physical problems 79.01±16.15, role limitation due to emotional problems 68.00±17.10, vitality 48.68±7.30, mental health 98.64±4.25, social functioning 87.22±18.71, bodily pain 80.61±12.67, general health 72.5±4.06 and reported health transition 82.71±12.89 and overall score at p-value was found to be significant. Conclusion: HRQoL of pregnant women associated with complications has been improved where mental health tends to recover more quickly than physical health. Keywords: Quality of Life; Anemia; UTI; Pre-eclampsia; Hyperemesis gravidarum.
- 11 December 2021
- Published by Wiley in Nephrology
- Vol. 27 (4) , 318-326
Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients
Background: Recently, multiple epidemiological studies have linked imatinib with the alteration of renal function in chronic myeloid leukaemia (CML) patients. This meta‐analysis aimed to summarize the impact of imatinib use on renal function in CML patients.Methods: A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle‐Ottawa scale (NOS). Two authors independently performed literature‐screening, risk of bias and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the grading of recommendations assessment, development and evaluation (GRADE) criteria.Results: A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta‐analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p < .05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (chronic kidney disease or acute kidney injury) was found to be significantly higher in imatinib users as compared to other tyrosine kinase inhibitor (TKI) users with a pooled relative risk of 2.70 (95% CI: 1.49–4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence.Conclusion: This meta‐analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.
- 11 December 2021
- Published by Wiley in Nephrology
- Vol. 27 (4) , 318-326
Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients
Background: Recently, multiple epidemiological studies have linked imatinib with the alteration of renal function in chronic myeloid leukaemia (CML) patients. This meta‐analysis aimed to summarize the impact of imatinib use on renal function in CML patients.Methods: A systematic search was conducted on MEDLINE and Embase to identify articles assessing the impact of imatinib exposure on renal function in CML patients. The risk of bias was assessed using the Newcastle‐Ottawa scale (NOS). Two authors independently performed literature‐screening, risk of bias and data extraction. The risk of renal dysfunction (chronic kidney disease or acute kidney injury) among imatinib users was computed as the primary outcome of interest. The certainty of findings was assessed using the grading of recommendations assessment, development and evaluation (GRADE) criteria.Results: A total of nine articles qualified for inclusion in the systematic review, of which four articles were eligible for meta‐analysis. Based on the scoring on NOS, majority of the included studies were found to be of moderate risk of bias. Majority of the studies (n = 6) reported significantly (p < .05) decrease in estimated glomerular filtration rate (eGFR) after imatinib treatment. The risk of developing renal dysfunction (chronic kidney disease or acute kidney injury) was found to be significantly higher in imatinib users as compared to other tyrosine kinase inhibitor (TKI) users with a pooled relative risk of 2.70 (95% CI: 1.49–4.91). Sensitivity analysis also revealed a consistently high risk of renal dysfunction with imatinib use. GRADE criteria revealed low certainty of evidence.Conclusion: This meta‐analysis found an increased risk of renal dysfunction in imatinib users compared to other TKI users.